Key facts
- Apmonia Therapeutics’s last known valuation is $26.8M (Oct 2025).
- It has raised $23.9M; the latest was Later Stage VC ($11.7M) in Feb 2026.
- Notable investors include Bpifrance, European Innovation Council, Capital Grand Est, Angels Santé, Business Angels Marne Ardennes — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Apmonia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Apmonia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apmonia Therapeutics
Developer of peptide-based biotechnology designed to provide therapeutic strategies for multiple types of cancer. The company focuses on creating drugs to treat glioblastoma, ovarian, colorectal, and pancreatic cancer, targeting the tumor microenvironment, and offers new therapeutic perspectives, particularly for the treatment of solid tumors, enabling patients to help fight cancer and helping researchers to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide.
- Sector
- Healthcare
- HQ
- Reims, France
- Founded
- 2019
- Employees
- 15
- Website
- apmonia-therapeutics.com/
- Ownership
- Privately Held (backing)
Apmonia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apmonia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apmonia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.